by Elena Iemma | Nov 30, 2021 | News
PROVIDENCE, RI, November 30, 2021 /PRNewswire/ — Today EpiVax, Inc. (“EpiVax”) confirmed that the company’s EPV-CoV-19 vaccine epitope sequences are 98.2% conserved in the new Omicron SARS-CoV-2 variant. EpiVax and EpiVax Therapeutics, Inc....
by Elena Iemma | May 17, 2021 | News
PROVIDENCE, RI, May 17, 2021 /PRNewswire/ — EpiVax, Inc. (“EpiVax”) announces the publication “Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation” in NPJ Vaccines. This research identifies...
by Annie De Groot | Sep 21, 2020 | Events, Webinars
Thank you for your continued interest in the status of our EpiVax’s EPV-CoV-19 Vaccine Program. This event has passed! But do not fear, there is a recording of the session available for access. Kindly fill out the information form linked below and an email...
by Adam | Jul 24, 2020 | News
Are we “Checking the Box” or Making Vaccines that work? We need a COVID-19 vaccine! From China to the US to Europe and even Africa, scientists are working tirelessly, if not at “warp speed”, to develop and test more than one COVID-19...
by Annie De Groot | Jun 11, 2020 | Events, Webinars
This webinar has ended, but we invite you to view the recorded recap here. Please join us on July 17, 2020 for our next live webinar, topic TBA! Please extend this invitation to any colleagues or associates you feel would benefit from attending. Participation is...
